MK3134

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Dementia

Phase 1

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

CompletedNCT00887601

Merck Sharp & Dohme LLCDementia

Start: 2007-08-31End: 2008-05-31Updated: 2015-07-30

EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)

CompletedNCT01110616

Merck Sharp & Dohme LLCDementia

Start: 2010-06-30End: 2010-10-31Updated: 2015-11-02